Background. Pneumococcal meningitis is a rare but potentially fatal complication of cochlear implantation. Methods. A prospective study was conducted of the immunogenicity of pneumococcal vaccination in 174 patients with cochlear implants (CIs). The cohort was divided into groups of patients with impaired hearing due to meningitis (P 1 ), cranial malformations (P 2 ), or an unknown cause (P 3 ) and was stratified by age as follows: !2 years (A 1 ), 2-5 years (A 2 ), and 15 years (A 3 ). We determined immunoglobulin (Ig) levels for IgG subclasses 1-4 and serum concentrations of antibodies against pneumococci before and 4-6 weeks after vaccination. Group A 1 received the 7-valent pneumococcal conjugate vaccine (PCV-7), group A 2 received PCV-7 or the 23-valent pneumococcal polysaccharide vaccine (PPV-23), and group A 3 received PPV-23.
Within the last decades, thousands of profoundly deaf children and adults worldwide have regained hearing with the help of cochlear implants (CIs). Starting in 2002, regulatory authorities noticed an increase in bacterial meningitis after cochlear implantation. The Food and Drug Administration (FDA) reported 87 cases of meningitis among patients who had undergone implantation with the 3 FDA-approved CI devices; most of these cases occurred in children !7 years of age. A total of 17 deaths worldwide has resulted from postimplantation meningitis (as of 2 October 2002) [1] . A retrospective study performed by the Centers for Disease Control and Prevention (CDC) identified a 130-fold increase in the in-cidence of pneumococcal meningitis among 4264 pediatric CI recipients in the United States, compared with the incidence in a cohort of healthy subjects of the same age [2] . Additional risk factors were malformations of the inner ear and/or a cerebrospinal fluid (CSF) leak and the use of a positioning device [2] . The latter was a wedge inserted next to the implanted electrode, which pushed the electrode against the medial wall of the cochlea, to improve transmission of the electrical stimulation. This device has been withdrawn from the market.
In the CDC study [1] , Streptococcus pneumoniae accounted for 62% and Haemophilus influenzae type b (Hib) or nontypeable strains for 21% of the cases of postimplantation bacterial meningitis due to a known cause. Of these cases, only 3 children had received 1 or 2 doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) before undergoing implantation. Two children acquired Hib meningitis despite having been vaccinated.
Many experts believe that most cases of postimplantation meningitis are due to anatomical predispositions and are directly related to the implantation of the CI. Thorough examinations of the immune competence of CI recipients have not been performed. Bearing in mind that patients with a history of meningitis might not respond sufficiently to routine vaccination, we investigated the specific immune response to polysaccharides in a cohort of patients with CIs.
PATIENTS AND METHODS

Patients.
At Frankfurt University Medical Center, 174 patients have been provided with a CI. Of these patients, 168 (96%) completed this study, and the rest moved abroad or were lost to follow-up. Patient ages at the time of the study were between 14 months and 27 years, with 7 patients 118 years of age; sex distribution was almost equal (87 male and 81 female patients). Patients were excluded if they had a history of allergic or serious adverse reactions to vaccines received previously. Other exclusion criteria were progressive neurological disease and therapy for any current illness. Each patient's individual and family medical histories were taken, with a focus on incidence of systemic bacterial infections, cranial dysplasia, and/ or inner-ear malformations. Informed consent was obtained from all patients and/or their parents or guardians. Guidelines for Good Clinical Practice, German Drug Act, and human experimentation guidelines of the Declaration of Helsinki/Hong Kong were followed in the conduct of clinical research, and approval by the ethical committee of the University of Frankfurt was obtained.
The cohort was subdivided into 3 clinical groups: patients with impaired hearing due to meningitis (P 1 ;
[13 male n p 17 and 4 female patients]; median age, 7.9 years) or to cranial malformations (P 2 ;
[1 male and 10 female patients]; n p 11 median age, 7.7 years; table 1) and patients with impaired hearing of unknown origin (P 3 ;
[73 male and 67 female n p 140 patients]; median age, 8.0 years). In group P 1 , S. pneumoniae infection was diagnosed for 14 (82%) of the 17 patients (confirmed by blood culture). A group of 21 healthy children (P 4 ; 14 male and 7 female subjects; median age, 5 years) from another study served as a historic control group for immunoglobulin values [3] . Furthermore, the cohort was stratified by age according to the following groups: A 1 We determined immunoglobulin levels for IgG subclasses 1-4 and serum concentrations of antibodies against pneumococci and Hib. Protection against Hib was presumed when antibody levels were у0.15 mg/mL. Depending on their age, the CI recipients were then vaccinated with PCV-7 or the 23-valent pneumococcal polysaccharide vaccine (PPV-23), in accordance with recommendations specified by US health authorities [1] . When we realized the weakness of the immune response to PPV-23 in the 2-5-year-old group, we modified the protocol for ethical reasons, and the rest of the patients in this age group received PCV-7. Thus, group A 2 was subdivided into groups A 2 -PPV- Serological analysis. Serum antibodies to the PCV-7 serotypes were determined before and 4-6 weeks after vaccination. Serotype-specific IgG antibody concentrations were measured by use of a modified ELISA technique using CovaLink microtiter plates (Nunc), as described elsewhere [4] . Serum samples were preincubated with 10 mg/mL pneumococcal capsular polysaccharide (CPS; Statens Seruminstitut), for blocking of nonspecific anti-CPS antibodies. Reference serum 89-SF (provided by Dr. Carl E. Frasch, Center for Biologics, Rockville, MD) was used for assay standardization [4] . In addition, serum samples were adsorbed against serotype 22F, to remove cross-reactive antibodies [5] . Minimum antibody-detection level was 0.05 mg/mL. IgG subclasses were measured by nephelometry assays, as described and adapted in a study of 159 healthy adults [6] . Hib antibody concentrations were determined by ELISA, by use of a commercial assay (Immunozym Hib IgG; Progen) [7] .
Criteria predicting protection from invasive pneumococcal disease. The debate concerning serological criteria that may predict protection against pneumococcal disease is ongoing. The consensus meeting report of the World Health Organization recommended a non-serotype-specific threshold antibody concentration of 0.2 mg/mL, after the third dose of pneumococcal vaccine, as predictive of protection for the general pediatric population [8] . This concentration can be regarded as a minimum protective level. Since our study population seemed to be at an increased risk for invasive pneumococcal disease and expansion of protection appeared to be desirable, we defined an antibody concentration of 1.0 mg/mL, after the first pneumococcal vaccination, as predictive of protection. This is consistent with the study by Sanders et al. [9] , who defined successful pneumococcal immunization as postvaccination antibody titers у1.0 mg/mL for at least 5 of 7 measured serotypes. Alternative parameters for the estimation of protection include geometric mean concentrations (GMCs) of antibodies and seroconversion rates, with the GMCs being favored as predictors of herd immunity and mucosal protection against vaccine-related serotypes. The proportion of responders reaching a threshold antibody level appears to be useful in estimating protection against invasive disease. 
Statistical analyses.
Antibody GMCs for all antigens were calculated by using pre-and postvaccination concentrations. GMCs and the proportions of patients with antibody concentrations у0.2 mg/mL and у1.0 mg/mL were determined for each pneumococcal serotype. Antibody levels before and after vaccination were compared by using the Wilcoxon test. The Mann-Whitney U test or a multidimensional H test (KruskalWallis) were done for between-group comparisons.
RESULTS
Immunoglobulin levels. Serum immunoglobulin levels ‫2ע‬ SD of the age-specific mean were considered to be normal. IgG, IgM, and IgG1 levels were significantly lower in group P 1 , compared with healthy control subjects (table 2). Levels of IgG subclasses that were below age-specific normal values were found in 2 (12%) of the 17 patients in group P 1 and in 2 (18%) of the 11 patients in group P 2 (1 with low IgG1 level and 1 with low IgG2 level in each of the 2 groups), versus 10 (7.1%) of the 140 patients in group P 3 (3 with low IgG1 levels and 7 with low IgG2 levels).
Hib antibody levels. Hib antibody concentrations were above the presumed protective level (0.15 mg/mL) in all patients, the majority of whom (137 [82%] of 168 patients) had previously received Hib vaccination.
Anti-pneumococcal serotype concentrations before vaccination. Prevaccination concentrations of antibodies to pneumococcal serotypes were low in the 3 clinically defined groups (table 3). Significant differences could be detected when comparing antibody concentrations for serotypes 4 ( ) and P p .03 9V ( ) in group P 1 with those in group P 3 . Because of P p .04 contact with wild-type pneumococci, prevaccination antibodies increased with age, as expected (table 4) .
Anti-pneumococcal serotype concentrations after 1 dose of pneumococcal vaccine. All vaccines were highly immunogenic, and each vaccine induced a statistically significant increase in Table 3 . Geometric mean concentrations, in mg/mL (95% confidence intervals), and P values of IgG antibodies for 3 groups of cochlear implant recipients, before and after pneumococcal vaccination. antibodies to all vaccine-specific pneumococcal serotypes (table  4) . When comparing group A 2 -PCV-7 with group A 2 -PPV-23, antibodies specific to serotypes 4, 6B, 18C, 19F, and 23F showed significantly stronger increases in GMCs in group A 2 -PCV-7. Prevalence of postvaccination antibody concentrations above the protective threshold. Prevalence of postvaccination antibody concentrations у1.0 mg/mL for pneumococcal serotypes was similar in the 3 clinically defined groups, ranging between 77.1% and 100% (table 5). The percentage of patients with antibody concentrations у1.0 mg/mL also increased as age increased. In group A 2 -PCV-7, the proportion of patients who reached our threshold concentration was larger than that in group A 2 -PPV-23. Almost all patients acquired antibody concentrations у0.2 mg/mL after the first vaccination (table 6).
DISCUSSION
Our prospective investigator-initiated study is the first examination of humoral immunity in CI recipients. In general, factors such as age, presumed CSF leaks, and immune status help estimate an individual's risk for pneumococcal meningitis. As epidemiological data prove, a history of meningitis is a major risk factor for recurrence in CI recipients [1] . Since these patients do not have an anatomic disposition for increased risk, other host factors, such as immunological incompetence, may be partially responsible for the increased risk.
Our results showed that IgG, IgM, and IgG1 levels were significantly lower in CI recipients with a history of bacterial meningitis, compared with healthy control subjects. This finding is in accordance with results of a recent Dutch study, which revealed significantly lower immunoglobulin and IgG2 levels in otitis-prone children, compared with healthy control subjects [10] . Normally, recurrent infections would induce high antibody levels, owing to repeated stimulation; our observed humoral hyporesponsiveness in group P 1 (implantation after meningitis) might indicate an ongoing susceptibility to capsulated pathogens.
Among our CI recipients, the proportion with prevaccination pneumococcal antibody titers у1.0 mg/mL (indicating longterm immunity in nonimmunized individuals) was surprisingly small. Even among patients 15 years of age, whose immune systems are relatively mature, the proportion of patients reaching this level was only 38%-88%, depending on the pneu- NOTE. Data are percentage of patients with IgG antibody concentration у1.0 mg/mL (or у0.2 mg/mL). P 1 , patients with impaired hearing due to meningitis; P 2 , patients with impaired hearing due to cranial malformation; P 3 , patients with unexplained hearing loss; PnC, pneumococcal serotype; x, median age of patients, in years. Table 6 . Prevalence of IgG antibody concentrations above the protective threshold for pneumococcal disease (у1.0 or у0.2 mg/mL) in 3 groups of cochlear implant recipients, stratified by age, before and after pneumococcal vaccination. NOTE. Data are percentage of patients with IgG antibody concentration у1.0 mg/mL (or у0.2 mg/mL). A 1 , patients !2 years of age; A 2 , patients 2-5 years of age; A 3 , patients 15 years of age; PCV-7, 7-valent pneumococcal conjugate vaccine; PnC, pneumococcal serotype; PPV-23, 23-valent pneumococcal polysaccharide vaccine; x, median age of patients, in years. mococcal serotypes considered. For patients in groups P 1 and P 2 , the situation appeared to be even worse, with antibody levels у1.0 mg/mL in 13.3%-60.0% and 9.1%-81.8% of patients, respectively. Moreover, patients with hearing loss after meningitis had significantly lower levels of antibodies against pneumococcal serotypes 4 and 9V than did CI recipients without this risk factor. This finding was unexpected and implies that the naturally acquired immune response to pneumococcal polysaccharides may be impaired in at least some of these patients. However, because of the small sample size of the groups, differences in immune response were not statistically significant for all serotypes. As expected, compared with patients with impaired hearing caused by an unknown condition, patients in group P 2 had smaller differences in immune response, because cranial or inner-ear malformations are an anatomic, rather than an immunological, predisposition for systemic bacterial infections.
In general, patients with impaired humoral immunity are prone to many bacterial infections. Some can be characterized by an inability to process polysaccharide antigens, such as the capsule of H. influenzae or pneumococcus [11] [12] [13] , even though antibody responses to protein vaccines are appropriate. The pathogenesis of this polysaccharide-specific immunodeficiency is not yet clearly understood. Several mechanisms have been suggested, such as a genetic disposition (e.g., the G2m[n] allotype) or defective expression of complement receptor-2 on B cells [14] . Irrespective of the underlying condition, PCVs have been found to be immunogenic for the majority of these patients and have been effective in a field trial involving HIVinfected children [3, 15, 16] .
Since data on the immunogenicity of PCV-7 in at-risk groups are still limited, our study investigated pneumococcal antibodies after the first vaccination. This strategy was meant to estimate the desired protection as early as possible. Our data suggest a relative protection as early as after the first pneumococcal vaccination, in all patients in the study, irrespective of the underlying cause of impaired hearing. This observation is of particular importance for high-risk populations, such as CI recipients, and challenges the CDC recommendations to vaccinate twice all CI recipients 2-5 years of age. Nonetheless, we are aware of the problem that absolute antibody concentrations do not necessarily correlate with immunological memory function in this particular patient population.
The existing CDC vaccination schedule for CI recipients 12 years of age recommends starting pneumococcal immunization with PCV-7. This procedure is not generally accepted, and some national guidelines still recommend vaccination only with PPV-23 for children 12 years of age. To evaluate these different recommendations, we vaccinated a subgroup of our 2-5-year-old CI recipients with PPV-23. Consistent with results reported by Barnett et al. [17] , this group demonstrated a weaker immune response than did the PCV-7-vaccinated patients in the same age group. No patient in the PPV-23-vaccinated group had a history of bacterial meningitis or laboratory data indicating immunodeficiency. Thus, there was no evidence for a selection bias. Since we changed the immunization protocol for this age group for ethical reasons, 2 different group sizes occurred (12 patients receiving PPV-23, and 26 patients receiving PCV-7), resulting in reduced statistical strength for our observations.
For CI recipients 15 years of age, existing vaccination schedules recommend PPV-23. In our view, the efficacy of PPV-23 in this group should be discussed. PPV-23 is meant to cover a broader spectrum of pneumococcal serotypes; nonetheless, it is well known that PPV-23 does not prevent mucosal disease, such as otitis, sinusitis, or mucosal colonization. As has been demonstrated for immunization against Hib, conjugate vaccine followed by polysaccharide vaccine increases immunogenicity and induces immunological memory even in individuals who initially do not respond to only 1 of the vaccines [18, 19] . Several possible explanations have been given: PCV-7 induces a significantly higher antibody titer than does PPV-23 alone and seems to induce mucosal immunological memory [20] [21] [22] . In addition, a reduction of nasopharyngeal carriage of pneumococci has been described for PCV-7 [23] [24] [25] [26] , and even the carriage of antibiotic-resistant, vaccine-specific pneumococcal serotypes was reduced 1 year after immunization [27] . This effect is of particular importance for CI recipients, since bacterial spread from colonized cranial mucosal surfaces is a major contributing factor in systemic pneumococcal infections.
We admit that this study does not prove a correlation between serum antibody concentrations and mucosal protection in our CI recipients. For ethical and medical reasons, it was impossible for us to perform paracentesis to obtain middle-ear fluid from our vaccine recipients, for antibody determination and bacterial testing. Thus, whether patients with CIs will benefit from combined vaccination with PCV-7 followed by PPV-23 is still a matter of debate. Indeed, Veenhoven et al. [28] recently challenged the efficacy of such a combined schedule for patients with recurrent otitis media, demonstrating a replacement of mucosal carriage of vaccine serotypes by nonvaccine serotypes in children 1-7 years of age who had undergone combined vaccination. On the other hand, invasive pneumococcal disease also plays an important role in the pathogenesis of bacterial meningitis in CI recipients. In contrast to these findings for otitis media, no replacement of serotypes has ever been observed for invasive pneumococcal disease, and PCV-7 is highly effective in preventing this life-threatening condition [29] . Finally, there is evidence that, in addition to inducing antibody production, even a single dose of a conjugate vaccine promotes an increase in antibody avidity [30, 31] . Higher antibody avidity is more cross-reactive with closely related pneumococcal serotypes, thus improving protection against pneumococcal infections. Overall, combined vaccination with PCV-7 followed by PPV-23 should be seriously considered as an important strategy for the protection of high-risk patients 15 years of age.
Meningitis seems to have recently emerged as a rare but significant cause of morbidity and mortality after cochlear implantation. IgG, IgM, and IgG1 levels were significantly diminished in CI recipients with a history of bacterial meningitis, suggesting a generalized decrease in antibody response. We recommend vaccination with PCV for all CI recipients р5 years of age and for CI recipients 15 years of age who have additional risk factors (e.g., history of bacterial meningitis, cranial malformation, or implantation by use of a positioning device). Those CI recipients at an increased risk should undergo an immunological evaluation, including determination of pneumococcal antibodies before and after vaccination.
